Drug intelligence / Profile preview

AVVA GLP1R agonist

Development stage: Preclinical
Lead developer: Avva Pharmaceuticals
Modality: Peptides
Administration: Subcutaneous

Overview

AVVA GLP1R agonist is a long-acting, biologic peptide-based therapeutic designed to target the glucagon-like peptide-1 receptor (GLP1R). Developed by AVVA Pharmaceuticals, this candidate is specifically engineered for high blood-brain barrier (BBB) permeability, distinguishing it from standard GLP-1 agonists typically used for type 2 diabetes and obesity. It is currently being investigated for the treatment of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease, where it aims to leverage the neuroprotective and anti-inflammatory effects of GLP-1 signaling within the central nervous system.

Other names: GLP1R AgonistGLP-1R AgonistGLP 1R Agonistlong-acting GLP-1 receptor agonist

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on AVVA GLP1R agonist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVVA GLP1R agonist.

Explore the full profile